A Randomized Phase 2 Trial for Myeloblative versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-Cell Lymphoma

Protocol: 
AAAQ0962
Phase: 
II

A Randomized Phase 2 Trial for Myeloblative versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-Cell Lymphoma

This is a research study to test the effects of chemotherapy and stem cell transplant compared with chemotherapy alone on primary central nervous system (CNS) B-cell lymphoma. This study will enroll 160 subjects age 18-75 years who have primary CNS B-cell lymphoma. All subjects will be randomly assigned in a 1:1 ratio to receive either chemotherapy alone or chemotherapy and stem cell transplant, following an initial chemotherapy treatment received by all subjects. Imaging scans will be used to determine the effectiveness of each treatment. As the best treatment for patients with primary CNS B-cell lymphoma is not known, this study may help identify an effective treatment with limited negative side effects.

Are you Eligible? (Inclusion Criteria)

-Subjects must have Diffuse large B-cell lymphoma confined to the CNS
-Subjects must not have had prior chemotherapy or radiation therapy for lymphoma
-Subjects must have no evidence or history of non-Hodgkin lymphoma (NHL) outside of CNS

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States